Saleem Uzma, Zubair Sidra, Riaz Amjad, Anwar Fareeha, Ahmad Bashir
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Govt. College University, Faisalabad 38000, Pakistan.
Riphah Institute of Pharmaceutical Sciences, Riphah International University Lahore, Lahore 54000, Pakistan.
ACS Omega. 2020 Aug 5;5(32):20481-20490. doi: 10.1021/acsomega.0c02587. eCollection 2020 Aug 18.
The study's aim was to explore the effect of venlafaxine, valsartan, and pramipexole on spermatogenesis. It was hypothesized that these drugs may affect the male fertility because of their long-term use in treatment of depression, hypertension, and Parkinson's diseases. Male rats were given venlafaxine, valsartan, and pramipexole at low- and high-dose levels orally once daily for 10 weeks. Testosterone (25 mg/kg) was given as a standard via an intramuscular route once weekly. Rats were sacrificed after blood collection by cardiac puncture, and testes were removed. Sperm parameters were examined from spermatozoa of the cauda epididymis, and testes were treated for histopathological analysis. Results showed nonsignificant effect of venlafaxine on the sperm count, whereas a decreased sperm count was noted in all the treatment groups as compared to that of the control except valsartan at a low dose, which significantly ( < 0.001) raised the sperm count (96.26 ± 2.4) in reference with the control value (49.13 ± 2.3). Treatments had variable effects on total sperm motility and morphological parameters, but valsartan at a low dose showed maximum sperm motility (71.55 ± 0.7) among all. DNA integrity of spermatozoa remained intact in all groups. Luteinizing hormone and follicle-stimulating hormone levels decreased, and testosterone levels increased in all treatment groups as compared to control values, which indicate fertility. Histopathology revealed normal texture of testes with venlafaxine and valsartan, but testicular damage occurred with high-dose pramipexole. It is concluded that the use of venlafaxine, valsartan, and pramipexole at a low dose is devoid of any harmful effect on spermatogenesis, whereas pramipexole at a high dose adversely affect it.
该研究的目的是探讨文拉法辛、缬沙坦和普拉克索对精子发生的影响。据推测，这些药物由于长期用于治疗抑郁症、高血压和帕金森病，可能会影响男性生育能力。雄性大鼠每天口服一次低剂量和高剂量的文拉法辛、缬沙坦和普拉克索，持续10周。每周通过肌肉注射途径给予睾酮（25mg/kg）作为标准剂量。通过心脏穿刺采血后处死大鼠，并取出睾丸。检查附睾尾部精子的精子参数，并对睾丸进行组织病理学分析。结果显示，文拉法辛对精子计数无显著影响，而与对照组相比，除低剂量缬沙坦外，所有治疗组的精子计数均下降，低剂量缬沙坦显著（<0.001）提高了精子计数（96.26±2.4），相对于对照组值（49.13±2.3）。治疗对精子总活力和形态参数有不同影响，但低剂量缬沙坦在所有组中显示出最大的精子活力（71.55±0.7）。所有组精子的DNA完整性均保持完整。与对照组值相比，所有治疗组的黄体生成素和促卵泡激素水平下降，睾酮水平升高，这表明具有生育能力。组织病理学显示，文拉法辛和缬沙坦治疗的睾丸质地正常，但高剂量普拉克索会导致睾丸损伤。结论是，低剂量使用文拉法辛、缬沙坦和普拉克索对精子发生没有任何有害影响，而高剂量普拉克索会对其产生不利影响。
